FDA
-
-
-
-
-
-
-
Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
-
-
-
-
-
-
-
Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
-
-
-
-
-
-
-
Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million
-
-
-
-
-
-
-
Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
-
-
-
-
-
-
-
Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris
-
-
-
-
-
-
-
Azitra announces 1-for-6.66 reverse stock split effective August 21
-
-
-
-
-
-
-
Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates
-
334,272 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


